Disease modifying treatments (DMTs): pre-treatment screening
Evidence-based neurology checklist on disease modifying treatments (dmts): pre-treatment screening: Tuberculosis screening Definite indications Considered indications Hepatitis B virus (HBV) screening Hepatitis C virus (HCV) screening HIV screening JC virus screening Aciclovir prophylaxis
Tuberculosis screening
- Definite indications
- Considered indications
Hepatitis B virus (HBV) screening
Hepatitis C virus (HCV) screening
HIV screening
JC virus screening
Aciclovir prophylaxis
References
- Epstein DJ, Dunn J, Deresinski S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5:ofy174.
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018; 90:777-788.
- Chalmer TA, Baggesen LM, Nørgaard M, Koch-Henriksen N, Magyari M, Sorensen PS; Danish Multiple Sclerosis Group. Early versus later treatment start in multiple sclerosis: a register-based cohort study. Eur J Neurol 2018; 25:1262-e110.
- Kavaliunas A, Manouchehrinia A, Stawiarz L, et al. Importance of early treatment initiation in the clinical course of multiple sclerosis. Mult Scler 2017; 23:1233-1240.
